Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sago polysaccharides are water-soluble, nondigestible carbohydrates isolated from the sago palm (*Metroxylon sagu*). They function as prebiotics by resisting digestion in the upper gastrointestinal tract and undergoing fermentation by the gut microbiome in the colon. This fermentation process promotes the growth of beneficial bacteria and increases the production of short-chain fatty acids (SCFAs). In preclinical models of high-fat-diet-induced obesity and type 2 diabetes, sago polysaccharides have been shown to improve glucose tolerance, insulin sensitivity, and gut barrier integrity, while reducing mucosal inflammation and modulating hypothalamic energy signaling via the gut-microbiome-brain axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sago polysaccharides.